CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: A tool for in vitro preclinical studies with primary B-cell malignancies

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1390-1398

  Ito, Daisuke ^a,b   Frantz, Aric M ^a,b   Williams, Christina ^c   Thomas, Rachael ^c   Burnett, Robert C ^d   Avery, Anne C ^d   Breen, Matthew ^c,e   Mason, Nicola J ^f,g   O'Brien, Timothy D ^a,b,h   Modiano, Jaime F ^a,b,h  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d Department of Ecosystem Science and Sustainability   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

canine model; CD40L; cytotoxicity assay; Diffuse large B cell lymphoma; primary cell culture

Indexed keywords

CD40 LIGAND;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOTOXICITY; DOG; FEEDER CELL; FLOW CYTOMETRY; GENE DOSAGE; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; KARYOTYPE; LARGE CELL LYMPHOMA; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; CD40 LIGAND; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDER CELLS; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 84862743178     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.654337     Document Type: Article

References (29)

1. Kuwashima N, Kageyama S, Eto Y, et al. CD40 ligand immunotherapy in cancer: an efficient approach. Leuk Lymphoma 2001;42:1367-1377. (Pubitemid 34082927)
2. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17. (Pubitemid 30046812)
3. Challa A, Eliopoulos AG, Holder MJ, et al. Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood 2002;99:3411-3418. (Pubitemid 34525324)
4. Pham LV, Tamayo AT, Yoshimura LC, et al. A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 2002;16:37-50. (Pubitemid 34143215)
5. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874. (Pubitemid 34028664)
6. Hömig-Hölzel C, Hojer C, Rastelli J, et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 2008;205:1317-1329. (Pubitemid 351831489)
7. Planken EV, Dijkstra NH, Willemze R, et al. Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the "CD40 system". Leukemia 1996;10:488-493. (Pubitemid 26128790)
8. Visser HP, Tewis M, Willemze R, et al. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia 2000;14:1483-1489. (Pubitemid 30599329)
9. Andersen NS, Larsen JK, Christiansen J, et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood 2000;96:2219-2225.
10. Spriggs MK, Armitage RJ, Strockbine L, et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992;176:1543-1550.
11. Funakoshi S, Longo DL, Beckwith M, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787-2794. (Pubitemid 24142707)
12. Henriquez NV, Floettmann E, Salmon M, et al. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1. J Immunol 1999;162:3298-3307. (Pubitemid 29313577)
13. French LE, Huard B, Wysocka M, et al. Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L. Blood 2005;105:219-225. (Pubitemid 40053086)
14. Wyzgol A, Müller N, Fick A, et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009;183:1851-1861.
15. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005;438:803-819. (Pubitemid 41753059)
16. Modiano J, Breen M, Valli V, et al. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia 2007;21:184-187. (Pubitemid 44921856)
17. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans - man and his best friend share more than companionship. Chromosome Res 2008;16:145-154. (Pubitemid 351294788)
18. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004;40:858-880. (Pubitemid 38519765)
19. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-156. (Pubitemid 351161319)
20. Kelsey JL, Moore AS, Glickman LT. Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol Rev 1998;20:204-217. (Pubitemid 29045107)
21. Mason N, Coughlin C, Overley B, et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene therapy 2008;15:955-965. (Pubitemid 351865752)
22. Ito D, Endicott MM, Jubala CM, et al. A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma. J Vet Intern Med 2011;25:890-896.
23. Thomas R, Seiser EL, Motsinger-Reif A, et al. Refining tumor-associated aneuploidy through "genomic recoding" of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leuk Lymphoma 2011;52:1321-1335.
24. Thomas R, Duke SE, Karlsson EK, et al. A genome assembly-integrated dog 1 Mb BAC microarray: a cytogenetic resource for canine cancer studies and comparative genomic analysis. Cytogenet Genome Res 2008;122:110-121.
25. Breen M, Hitte C, Lorentzen TD, et al. An integrated 4249 marker FISH/RH map of the canine genome. BMC Genomics 2004;5:65.
26. Vallera DA, Oh S, Chen H, et al. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther 2010;9:1872-1883.
27. Vallera DA, Chen H, Sicheneder AR, et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009;33:1233-1242.
28. Scott MC, Sarver AL, Gavin KJ, et al. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone 2011;49:356-367.
29. Rütgen BC, Hammer SE, Gerner W, et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res 2010;34:932-938.